PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
22 févr. 2024 08h30 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
30 janv. 2024 08h00 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
PRO3-420-A ProSomnus, Inc Logo_horizontal.png
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29 janv. 2024 08h00 HE | ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ihl_logo.png
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
29 nov. 2023 13h40 HE | Incannex Healthcare
MELBOURNE, Australia and NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex...
TIP_link_300x300.jpg
Americas Sleep Apnea Market Worth $4.10 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
10 nov. 2023 05h46 HE | The Insight Partners
Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Sleep apnea is a potentially serious sleep disorder where breathing repeatedly stops and starts. Such a condition prevents the patient's body from...
TIP_link_300x300.jpg
Sleep Apnea Implants Market Worth $803.26 Million by 2030 - Exclusive Report by The Insight Partners
18 oct. 2023 08h18 HE | The Insight Partners
Pune, India, Oct. 18, 2023 (GLOBE NEWSWIRE) -- North America accounted for the largest share of the global sleep apnea implants market in 2022. The North America sleep apnea implants market has...
Apnimed.png
Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
18 oct. 2023 08h00 HE | Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed.png
Apnimed to Participate in Upcoming October Investor Conferences
11 oct. 2023 08h00 HE | Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed.png
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
10 oct. 2023 08h30 HE | Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed.png
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
02 oct. 2023 08h00 HE | Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors